certepetide

Peptide

Ungradedevidence

Evidence outlook

Mid- and late-stage studies completed

This drug has completed mid- or late-stage studies. Where a sponsor has not posted registry results, topline data typically arrives via company announcements; see News.

Company guidance: data expected in 2026 (NCT05042128; Lisata Therapeutics, 13 Nov 2026). “Additional data from Cohorts A and B was presented at the ESMO annual meeting in October 2025 with a final study report of the ASCEND study anticipated to be made available in 2026.” Source ↗

The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (3)
Pancreatic Cancer
Other / comorbidity
NCT05712356 · Lisata Therapeutics, Inc.
2023-05-13 – 2026-04-05 · Cholangiocarcinoma, Gallbladder Cancer, Gallbladder Carcinoma, Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma, Bile Duct Cancer, Gall Bladder Cancer, Gall Bladder Carcinoma
What this study did
Phase 1/2 (3)
Pancreatic Cancer
NCT06592664 · Lisata Therapeutics, Inc.
2030-01 – 2040-01 · Pancreas Cancer, Pancreatic Carcinoma, Pancreas Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Unresectable Pancreatic Cancer, Metastatic Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
What this study did
NCT05052567 · Qilu Pharmaceutical Co., Ltd.
2021-10-21 – 2024-06-29 · Pancreatic Cancer
What this study did
Other / comorbidity
NCT05121038 · Anup Kasi
2021-10-20 – 2026-09 · Colon Cancer, Pancreas Cancer, Digestive Cancer
What this study did
Phase 1 (2)
Pancreatic Cancer
Other / comorbidity
NCT06216561 · University of California, San Diego
2023-11-30 – 2024-06-24 · Colorectal Cancer, Ovarian Carcinoma, Appendix Cancer, Peritoneal Metastases
What this study did

Competitive landscape

This drug's own stage for Pancreatic Cancer: Phase 2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Certepetide: this drugPhase 2PeptideAlpha-v integrins and neuropilin-1 (CendR tumour-penetration pathway)not yet gradedNo reviewed efficacy summary in this indication
Capecitabine
ApprovedUS marketing discontinued
Small moleculeFluoropyrimidine (antimetabolite)not yet gradedNo reviewed efficacy summary in this indication
ErlotinibApprovedSmall moleculeEGFRPartial signalNo reviewed efficacy summary in this indication
Gemcitabine
ApprovedUS marketing discontinued
Small moleculeribonucleotide reductase / DNA polymerase (dCTP competition)not yet gradedNo reviewed efficacy summary in this indication
OlaparibApprovedSmall moleculePARPnot yet gradedNo reviewed efficacy summary in this indication
AtebimetinibPhase 3Small moleculeMEK (MAP2K1/2)not yet gradedNo reviewed efficacy summary in this indication
HRS-4642Phase 3UndisclosedKRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12Dnot yet gradedNo reviewed efficacy summary in this indication
TertomotidePhase 3PeptideTelomerase (hTERT)not yet gradedNo reviewed efficacy summary in this indication
ZoldonrasibPhase 3Small moleculeKRAS G12Dnot yet gradedNo reviewed efficacy summary in this indication
MotixafortidePhase 2PeptideCXCR4not yet gradedNo reviewed efficacy summary in this indication
Nogapendekin Alfa Inbakicept (Anktiva)Phase 2Protein / enzyme therapeuticIL-15 superagonistnot yet gradedNo reviewed efficacy summary in this indication
A2B530Phase 1/2Cell therapyCEA / carcinoembryonic antigen (activator) / HLA-A*02 (blocker)not yet gradedNo reviewed efficacy summary in this indication
KRAS-Specific Autologous TCR-T Cell
Phase 1(overall)
Cell therapyKRAS G12V presented on HLA-A*11:01not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

26 June 2025Topline resultASCEND Phase 2b Cohort B preliminary results
22 January 2025Topline resultPreliminary Cohort A data from Phase 2 ASCEND trial